BeyondSpring (NASDAQ:BYSI) Price Target Lowered to $4.00 at Robert W. Baird

Posted by Lauren Steadman on Mar 19th, 2023

BeyondSpring (NASDAQ:BYSI – Get Rating) had its price objective cut by Robert W. Baird from $11.00 to $4.00 in a report published on Wednesday, The Fly reports.

BeyondSpring Stock Performance

BeyondSpring stock opened at $1.24 on Wednesday. BeyondSpring has a fifty-two week low of $0.54 and a fifty-two week high of $3.45. The stock has a market cap of $48.27 million, a PE ratio of -0.76 and a beta of 0.11. The firm’s 50-day simple moving average is $2.11 and its 200 day simple moving average is $1.44.

Institutional Trading of BeyondSpring

Several hedge funds have recently added to or reduced their stakes in BYSI. BlackRock Inc. raised its position in BeyondSpring by 20.8% in the first quarter. BlackRock Inc. now owns 1,861,219 shares of the company’s stock worth $4,095,000 after acquiring an additional 320,428 shares during the period. Millennium Management LLC raised its position in shares of BeyondSpring by 78.0% in the second quarter. Millennium Management LLC now owns 691,826 shares of the company’s stock valued at $996,000 after purchasing an additional 303,184 shares during the period. Renaissance Technologies LLC increased its holdings in BeyondSpring by 831.9% during the 1st quarter. Renaissance Technologies LLC now owns 282,373 shares of the company’s stock worth $621,000 after acquiring an additional 252,073 shares during the period. BNP Paribas Arbitrage SA increased its holdings in BeyondSpring by 89.6% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 249,308 shares of the company’s stock worth $359,000 after acquiring an additional 117,831 shares during the period. Finally, XTX Topco Ltd bought a new stake in BeyondSpring during the 1st quarter worth approximately $159,000. Institutional investors own 18.14% of the company’s stock.

BeyondSpring Company Profile

(Get Rating)

BeyondSpring, Inc engages in the development and commercialization of immuno-oncology cancer therapies. It operates through the PRC and U.S. geographical segments. The company was founded by Lan Huang and Lin Qing Jia in 2010 and is headquartered in New York, NY.